Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07195604 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Single Ascending Dose of HRS-2162 in Healthy Subjects

StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Final enrollment: 8 participants (planned 64) · Primary completion date changed from estimate of Dec 2025 to Oct 9, 2025 · Eligibility criteria expanded, about 15 words · 2 more Show 5 more changesShow less
    • Final enrollment: 8 participants (planned 64)
    • Primary completion date changed from estimate of Dec 2025 to Oct 9, 2025
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 2 of 7 entries
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 2025 to Sep 25, 2025 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Sep 2025 to Sep 25, 2025
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is being conducted to evaluate the safety and tolerability of HRS-2162 injection in a single dose in healthy subjects, as well as the characteristics of PK/PD
Trial Details
NCT Number NCT07195604
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Reversal of Neuromuscular Blockade
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov